ECM
SRNE

Endurant Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Endurant Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-97,940
Closed -$1.13M – 108
2015
Q1 		$1.13M Sell
97,940
-50,313
-34% -$582K 0.37% 68
2014
Q4 		$1.49M Buy
+148,253
New +$751K 0.59% 49

Other funds holding SRNE

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Endurant Capital Management's SRNE Position: Q2 2015 in Review

Endurant Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2015, closing a stake of 97,940 shares — an estimated $1.13M sold.

Endurant Capital Management first reported a position in SRNE in Q4 2014 and held it in 2 quarters. The position peaked at $1.49M in Q4 2014. 75 funds tracked by Wall St. Rank hold SRNE as of Q2 2015.

  • Endurant Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Endurant Capital Management sold 97,940 Sorrento Therapeutics, Inc. shares in Q2 2015, an estimated $1.13M.
  • Endurant Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
  • Endurant Capital Management's Sorrento Therapeutics, Inc. position peaked at $1.49M in Q4 2014.
  • 75 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2015.

Based on Endurant Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.